10-Q: Aspire Biopharma Q3 Loss Widens, Sublingual Aspirin Progresses

Aspire Biopharma Holdings, Inc. reported a significant net loss for Q3 2025, alongside progress in its sublingual aspirin clinical trials and ongoing Nasdaq delisting concerns.

Summary

• Net loss for the nine months ended September 30, 2025, was $19,773,114, a substantial increase from $544,162 in the prior year.
• Generated first-time net revenue of $1,941 from nutraceutical products for the nine months ended September 30, 2025.
• Cash balance increased significantly to $1,948,271 as of September 30, 2025, from $3,633 at December 31, 2024, primarily due to financing activities.
• Working capital deficit grew to $11,457,377 as of September 30, 2025.
• Completed a reverse acquisition on February 17, 2025, changing the company name to Aspire Biopharma Holdings, Inc.
• Successfully completed a clinical trial for its high-dose sublingual aspirin product in July 2025, with positive results showing faster bioavailability and quicker anti-coagulant effects.
• Plans a 505(b)(2) submission to the FDA for its high-dose aspirin in early 2026, seeking Fast Track designation.
• Received Nasdaq delisting notices on April 16, 2025, for failing to meet minimum Market Value of Listed Securities ($50,000,000) and minimum bid price ($1.00), and has requested a hearing.
• Management concluded that disclosure controls and procedures were not effective as of September 30, 2025.

Sentiment

Score: 3

Explanation: While there's progress in product development and initial revenue, the significant increase in net loss, substantial going concern doubt, Nasdaq delisting threat, and ineffective internal controls paint a very negative financial and operational picture. The capital raises are critical but also highlight the ongoing need for funding and potential dilution.

Positives

• Generated initial net revenue of $1,941 from nutraceutical products for the nine months ended September 30, 2025, compared to none in the prior year.
• Cash balance significantly increased to $1,948,271 as of September 30, 2025, from $3,633 at December 31, 2024, primarily due to proceeds from financing activities.
• Successfully completed a clinical trial for its high-dose sublingual aspirin product in July 2025, with the final report in August 2025 showing positive results for faster bioavailability and quicker anti-coagulant properties.
• Filed new patent applications for its aspirin formulation technology (PCT/US2024/022318 and 63/702,381) and an omnibus patent for other drugs/supplements in October 2025.
• Unveiled and began selling initial versions of caffeine products in Q3 2025.

Negatives

• Reported a significant net loss of $19,773,114 for the nine months ended September 30, 2025, compared to $544,162 for the same period in 2024.
• Accumulated deficit increased to $22,550,347 as of September 30, 2025.
• Working capital deficit increased to $11,457,377 as of September 30, 2025.
• Operating expenses surged to $17,502,751 for the nine months ended September 30, 2025, primarily due to $14.1 million in stock-based compensation.
• Received Nasdaq delisting notices for failing to meet minimum Market Value of Listed Securities ($50,000,000) and minimum bid price ($1.00 per share) requirements.
• Management determined that disclosure controls and procedures were not effective as of September 30, 2025.
• Experienced high management turnover with two CEO changes within a few months.
• Incurred a $364,109 loss on extinguishment of debt related to the Blackstone Note amendment.

Risks

• Substantial doubt about the ability to continue as a going concern through the next twelve months due to liquidity conditions and accumulated deficit.
• Risk of delisting from Nasdaq due to failure to meet minimum Market Value of Listed Securities ($50,000,000) and minimum bid price ($1.00 per share) requirements. There is no assurance that the Panel will grant continued listing or that compliance will be regained.
• Future capital requirements are significant, and there is no assurance that additional financing can be raised on acceptable terms or at all, which would materially and adversely affect the business.
• The effectiveness of disclosure controls and procedures was deemed not effective, particularly for complex accounting areas, which could lead to errors or fraud.
• Reliance on third parties for manufacturing product candidates, with potential for insufficient capacity or compliance issues.
• Intense competition in the biopharmaceutical industry from companies with substantially greater resources.
• Commercial success depends on obtaining and maintaining intellectual property protection; some previously acquired patent properties expired, and a trademark was cancelled.
• The ELOC agreement may not result in increased liquidity due to the floor price and current market price.

Future Outlook

Aspire Biopharma plans to generate revenue by developing and marketing drugs and nutraceuticals using its sublingual delivery technology. The company intends to pursue licensing or collaboration agreements for development funding and milestone payments. A 505(b)(2) submission to the FDA for its high-dose aspirin product is targeted for early 2026, with a goal of Fast Track designation. Further clinical trials may be conducted to differentiate its aspirin product based on TXB2 inhibition and gastrointestinal irritation. The company is also developing sublingual formulations for melatonin, vitamins D/E/K, semaglutide, anti-nausea, anti-psychotic, ED drugs, and seizure medication, with plans to take several to market as R&D, market conditions, and funding dictate. General and administrative, research and development, and sales and marketing expenses are expected to increase with business growth and public company status.

Management Comments

• Management has determined that the Company's liquidity condition raises substantial doubt about the Company's ability to continue as a going concern through twelve months from the date these condensed consolidated financial statements are available to be issued.
• Aspire expects that its general and administrative expenses will increase in future periods commensurate with the expected growth of its business and increased expenditures associated with its status as an exchange listed public company.
• Aspire expects that its research and development expense will increase in future periods commensurate with the expected growth of its business.
• Aspire expects that its sales and marketing expense will increase in future periods commensurate with the expected growth of its business.
• The Company is currently undergoing a search for a permanent CEO with appropriate experience.
• Management of the Company, including its Chief Executive Officer and its Chief Financial Officer, does not expect that the Company's disclosure controls and procedures or its internal control over financial reporting will prevent or detect all error and all fraud.
• Our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) were not effective including those controls surrounding complex accounting areas such as the Company's recapitalization.

Industry Context

Aspire Biopharma operates in the highly competitive and rapidly evolving biopharmaceutical and supplements industry, characterized by continuous technological advancements and a strong emphasis on proprietary products. The company's focus on novel sublingual delivery mechanisms for known drugs like aspirin and caffeine positions it in a niche aiming for faster absorption and reduced side effects. However, it faces significant competition from established pharmaceutical giants and smaller biotech firms with greater resources. The market for aspirin, a century-old drug, is mature, and Aspire's success hinges on differentiating its sublingual product through superior efficacy (faster action, reduced GI toxicity) and securing FDA approval. The company's entry into nutraceuticals like caffeine and melatonin aligns with growing consumer interest in health supplements, but these markets are also highly competitive and less regulated than prescription drugs.

Comparison to Industry Standards

• The positive clinical trial results for sublingual aspirin, demonstrating faster bioavailability and quicker anti-coagulant properties compared to standard oral aspirin tablets, suggest a potential competitive advantage in the acute myocardial infarction treatment market. This could differentiate it from existing oral aspirin products like Bayer aspirin.
• The company's strategy to target the heart attack and stroke prevention market through a specialized hospital and/or specialty care sales force is a common approach for novel drug delivery systems in critical care.
• The pursuit of FDA 505(b)(2) Fast Track designation for its high-dose aspirin product leverages the known safety profile of aspirin, a strategy often employed by companies developing new formulations of existing drugs to expedite approval compared to entirely new chemical entities.
• The development of sublingual melatonin and caffeine products places Aspire in direct competition with numerous established supplement brands, where differentiation will rely on the perceived benefits of sublingual delivery (e.g., faster onset) and effective marketing, rather than FDA approval.
• The company's significant accumulated deficit and going concern warning are not uncommon for early-stage biopharmaceutical companies, which typically incur substantial R&D and operational losses before commercialization. However, the magnitude of the net loss and working capital deficit, coupled with Nasdaq delisting threats, indicates a more precarious financial position compared to well-capitalized industry peers.
• The ineffectiveness of disclosure controls and procedures is a serious governance issue that falls below industry best practices for public companies, regardless of size.

Management Changes

Corporate Governance

Legal Proceedings

• Received Nasdaq delisting notices on April 16, 2025, for non-compliance with minimum Market Value of Listed Securities ($50,000,000) and minimum bid price ($1.00 per share) rules. The company has requested a hearing to present a plan to regain compliance.
• Received two default notices on April 1, 2025, citing failure to timely file Form 10-K and late filing of Form S-1, and a cross-default to the Securities Purchase Agreement. These were resolved via a settlement agreement on April 24, 2025, with lenders withdrawing notices and amending loan agreements.

Related Party Transactions

• Loan and Transfer Agreements: Assumed $250,000 from SSVK Associates, LLC, $50,000 from Apogee Pharma (with 50,000 shares issued as commitment fees), $149,214 from Jinal Sheth, and $50,000 from Apogee Pharma 2, all through the New Sponsor.
• Subscription Agreements: Assumed $1,500,000 of debt under First and Second Subscription Agreements, with 1,750,000 commitment fee shares transferred by affiliates to investors.
• Due to Affiliate: Assumed $353,679 of liabilities due to the Sponsor of PowerUp for administrative services fees and residual IPO proceeds.
• Promissory Note Fee: Agreed to pay the Sponsor a modified promissory note fee of $1,000,000 upon successful closing of a merger.
• Notes Payable Related Party: Issued several non-convertible 20% OID notes to related parties totaling $1,479,894 face value (before repayments and amendments), with 5% exit fees.
• Blackstone Subscription Agreement: Entered into an agreement with Blackstone Capital Advisors, Inc. (controlled by former Director of Investor Relations Lance Friedman) for up to $500,000 loan, with 1,795,000 commitment shares issued. This note was fully repaid in August 2025.
• Securities Purchase Agreement (Feb 17, 2025): Entered with Cobra Alternative Capital Strategies, LLC (controlled by Lance Friedman) and Target Capital X LLC, issuing convertible debentures and 2,106,527 SPA Commitment Shares.
• Corporate Advisory Agreement: Aspire Biopharma, Inc. entered an agreement with an advisory firm (affiliated company) for 4.75% of shares outstanding after the Reverse Acquisition, resulting in 1,662,500 shares issued and $14,131,250 in stock-based compensation.

Stakeholder Impact

• Shareholders: Face significant dilution risk from ongoing capital raises and convertible note conversions (e.g., 9.9M shares in Oct 2025, 48M shares in Nov 2025). The Nasdaq delisting threat poses a risk to liquidity and market value of shares. The substantial accumulated deficit and going concern warning indicate high financial risk.
• Employees: The company's early stage and going concern doubt may create uncertainty regarding job security and long-term stability.
• Customers: Potential for new sublingual aspirin and nutraceutical products offers new treatment options and supplements.
• Creditors: Subordination agreements and extended maturity dates on notes indicate ongoing financial strain, though some notes have been repaid. The company's ability to repay debt depends on future financing.
• Regulatory Bodies (FDA, Nasdaq): The company is actively engaging with the FDA for product approvals and with Nasdaq regarding listing compliance, indicating ongoing regulatory scrutiny and compliance efforts.

Next Steps

• File a 505(b)(2) submission to the FDA for the high-dose aspirin product in early 2026, seeking Fast Track designation.
• Continue discussions with the FDA regarding the possibility of selling an OTC Monograph aspirin product and potentially dropping the gastric issues warning.
• Potentially conduct a later clinical trial for high-dose aspirin to evaluate pharmacodynamic effect on platelet inhibition and differentiate from standard oral aspirin.
• Potentially conduct additional clinical trials focused on gastrointestinal irritation, ulceration, and bleeding for longer-term aspirin use.
• Conduct a limited pharmacokinetic study for sublingually administered melatonin.
• Explore licensing possibilities for melatonin.
• Patent the melatonin formulation in due course.
• Patent sublingually administered vitamins D, E, and K in due course.
• Continue developing a working formulation for a sublingual semaglutide product.
• Take other developed products (anti-nausea, anti-psychotic, ED drugs, seizure medication) to market as research and development, market conditions, and company funding dictate.
• Present a plan to regain compliance with Nasdaq's MVLS and Bid Price Rules at a hearing.
• Continue the search for a permanent Chief Executive Officer.
• File a PCT application on October 1, 2025, claiming priority to U.S. Application No. 63/702,381.
• File an omnibus patent in October 2025 to extend intellectual property rights to cover many other classes of drugs and supplements.

Key Dates

Recommendation

Aspire Biopharma faces severe financial distress, evidenced by a substantial net loss of nearly $20 million for the nine months, a growing accumulated deficit, and a formal 'going concern' warning from management. The company is also under imminent threat of delisting from Nasdaq due to failing to meet minimum market value and bid price requirements, which would significantly impair liquidity and investor confidence. While there is some positive news regarding clinical trial results for its sublingual aspirin and initial revenue from nutraceuticals, these developments are overshadowed by the company's precarious financial position, high cash burn, and ineffective internal controls. The reliance on continuous, highly dilutive capital raises to sustain operations, coupled with significant management turnover, indicates a high-risk investment with a strong likelihood of further share price depreciation and potential loss of investment.

Keywords

Biopharma, Sublingual Delivery, Aspirin, Nutraceuticals, SEC Filing, 10-Q, Financial Results, Nasdaq Delisting, Going Concern, Clinical Trials, Drug Development, Capital Raise, ASBP, Pharmaceuticals, Caffeine, Melatonin, Patent Application